WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2014182944) COMPOSITIONS AND METHOD FOR TREATMENT OF ISCHEMIC NEURONAL REPERFUSION INJURY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2014/182944    International Application No.:    PCT/US2014/037362
Publication Date: 13.11.2014 International Filing Date: 08.05.2014
IPC:
A61K 31/4166 (2006.01), A61K 31/5513 (2006.01), C07C 211/35 (2006.01)
Applicants: HOWARD UNIVERSITY; 2400 Sixth Street, N.W. Washington, D.C. (US)
Inventors: MANGAT, Harpal S.; (US).
KARLA, Pradeep K.; (US)
Agent: KRATZ, Rudy; (US)
Priority Data:
61/821,123 08.05.2013 US
Title (EN) COMPOSITIONS AND METHOD FOR TREATMENT OF ISCHEMIC NEURONAL REPERFUSION INJURY
(FR) COMPOSITIONS ET MÉTHODE DE TRAITEMENT DES LÉSIONS NEURONALES DE REPERFUSION ISCHÉMIQUE
Abstract: front page image
(EN)A method and composition for the treatment of ischemic neuronal reperfusion injury are provided. The composition may include at least a benzodiazepine class material. In another form, the composition may include at least two components selected from the group consisting of an antagonist of the type 3 ryanodine receptor, an NMDA blocker (antagonist), and a benzodiazepine class material which can be administered for ischemic neuronal reperfusion injury. In one form, all three components may be used.
(FR)L'invention concerne une méthode et une composition de traitement des lésions neuronales de reperfusion ischémique. La composition peut comprendre au moins un matériau de type benzodiazépine. Dans une autre forme, la composition peut comprendre au moins deux composants choisis dans le groupe constitué par un antagoniste du récepteur de la ryanodine de type 3, un antagoniste des récepteurs NMDA et un matériau de type benzodiazépine qui peuvent être administrés en cas de lésions neuronales de reperfusion ischémique. Dans une forme, les trois composants peuvent tous être utilisés.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)